Schneider, Jaime L. http://orcid.org/0000-0003-2591-2279
Shaverdashvili, Khvaramze
Mino-Kenudson, Mari http://orcid.org/0000-0002-9092-2265
Digumarthy, Subba R.
Do, Andrew http://orcid.org/0000-0002-5782-5818
Liu, Audrey
Gainor, Justin F. http://orcid.org/0000-0001-8697-4081
Lennerz, Jochen K. http://orcid.org/0000-0003-2434-4978
Burns, Timothy F. http://orcid.org/0000-0002-8685-3762
Lin, Jessica J. http://orcid.org/0000-0001-7373-3916
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA164273)
Article History
Received: 3 August 2023
Accepted: 6 October 2023
First Online: 3 November 2023
Competing interests
: J.L.S. has received honoraria from the Academy of Continued Healthcare Learning, Springer Healthcare, Targeted Oncology, and Dava Oncology. S.R.D. has received honorarium from Elsevier, Siemens; received research funding from Lunit Inc., GE, QURE AI, Vuno; is a member of the Speakers’ Bureau for Siemens; and provides independent image analysis for hospital-contracted clinical trials programs for Merck, Pfizer, Bristol Myers Squibb, Novartis, Roche, Polaris, Cascadian, Abbvie, Gradalis, Bayer, Zai Laboratories, Biengen, Resonance, Analise. J.F.G. has served as a compensated consultant for Amgen, Arcus Biosciences, AI Proteins, AstraZeneca, Beigene, Blueprint Medicines, Bristol Myers Squibb, Genentech/Roche, EMD Serono, InterVenn Biosciences, Gilead Sciences, iTeos Therapeutics, Jounce Therapeutics, Karyopharm Therapeutics, Lilly, Loxo, Merus, Mirati Therapeutics, Pfizer, Sanofi, Silverback Therapeutics, Merck, Moderna Therapeutics, Mariana Oncology, Takeda; has received honorarium from Merck, Pfizer, Novartis, Pfizer, Takeda; has received research funding from Adaptimmune, Alexo Therapeutics, Array BioPharma, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Genentech, Jounce Therapeutics, Merck, Moderna Therapeutics, Novartis, Tesaro; has an immediate family member who is an employee with stock and other ownership interests in Ironwood Pharmaceuticals; and has equity in AI Proteins. M.M.K. has acted as a paid consultant for AstraZeneca, Janssen Oncology, Repapre, Innate, Sanofi, Daiichi-Sankyo, and AbbVie and received royalties from Elsevier but declares no non-financial competing interests. T.F.B. has served as compensated consultant for DSMB: Advarra, Inc. (Lantern Pharma), Scientific Advisory Board: (no stock) Janssen Scientific Affairs, LLC, Jazz Pharmaceuticals Inc., Blueprint Medicines Corporation (BPMC), Emd Serono Inc., Mirati Therapeutics, Inc., Amgen, AstraZeneca, and Takeda Pharmaceuticals USA, Inc., and received institutional research funds from Novartis. JJL has served as a compensated consultant for Genentech, Regeneron, C4 Therapeutics, Blueprint Medicines, Nuvalent, Bayer, Elevation Oncology, Novartis, Mirati Therapeutics, Ellipses, CLaiM Therapeutics, Pfizer, Turning Point Therapeutics, and received institutional research funds from Hengrui Therapeutics, Turning Point Therapeutics, Neon Therapeutics, Relay Therapeutics, Bayer, Elevation Oncology, Roche, Linnaeus Therapeutics, Nuvalent, and Novartis. The remaining authors declare no competing interests.